Minimal Hepatic Encephalopathy Clinical Trial
Official title:
Minimal Hepatic Encephalopathy is Associated With Increased Cerebral Vascular Resistance. a Transcranial Doppler Ultrasound Study
NCT number | NCT04077125 |
Other study ID # | 1712 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 18, 2018 |
Est. completion date | March 1, 2019 |
Verified date | August 2019 |
Source | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a
relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools
for the early identification of affected patients.
This study was aimed to investigate cerebral blood flow, systemic hemodynamics as well as
endothelial function of cirrhotic patients with MHE, and to verify their change after
treatment with rifaximin.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 1, 2019 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of liver cirrhosis on the basis of clinical, laboratory and ultrasound findings Exclusion Criteria: - active alcohol abuse (excessive alcohol intake stopped more than 6 months before the enrollment); - chronic pulmonary diseases; ongoing infections; cerebrovascular diseases; primary or secondary cerebral neoplasm; primary liver neoplasm; heart function failure; chronic kidney disease; peripheral vascular disease; treatment with rifaximin or systemic antibiotics in the previous 15 days; - smoking habit; - grade 1 or overt hepatic encephalopathy. |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Agostino Gemelli IRCCS | Roma |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantification of middle cerebral artery resistive index | Quantification of middle cerebral artery resistive index by Doppler ultrasound in patients with liver cirrhosis with or without MHE | baseline | |
Primary | Quantification of middle cerebral artery pulsatility index | Quantification of middle cerebral artery pulsatility index by Doppler ultrasound in patients with liver cirrhosis with or without MHE | baseline | |
Primary | Quantification of posterior cerebral artery resistive index | Quantification of posterior cerebral artery resistive index by Doppler ultrasound in patients with liver cirrhosis with or without MHE | baseline | |
Primary | Quantification of posterior cerebral artery pulsatility index | Quantification of posterior cerebral artery pulsatility index by Doppler ultrasound in patients with liver cirrhosis with or without MHE | baseline | |
Primary | Change in middle cerebral artery resistive index after treatment with rifaximin | Variation of middle cerebral artery resistive index measured by Doppler ultrasound after treatment with rifaximin 1200 mg/d for 15 days in patients with liver cirrhosis and MHE | at the end of rifaximin treatment (15 days) | |
Primary | Change in middle cerebral artery pulsatility index after treatment with rifaximin | Variation of middle cerebral artery pulsatility index measured by Doppler ultrasound after treatment with rifaximin 1200 mg/d for 15 days in patients with liver cirrhosis and MHE | at the end of rifaximin treatment (15 days) | |
Primary | Change in posterior cerebral artery resistive index after treatment with rifaximin | Variation of posterior cerebral artery resistive index measured by Doppler ultrasound after treatment with rifaximin 1200 mg/d for 15 days in patients with liver cirrhosis and MHE | at the end of rifaximin treatment (15 days) | |
Primary | Change in posterior cerebral artery pulsatility index after treatment with rifaximin | Variation of posterior cerebral artery pulsatility index measured by Doppler ultrasound after treatment with rifaximin 1200 mg/d for 15 days in patients with liver cirrhosis and MHE | at the end of rifaximin treatment (15 days) | |
Secondary | Comparison of renal artery resistive index of cirrhotic patients with MHE compared to those without | Comparison of renal artery resistive index measured by Doppler ultrasound of cirrhotic patients with MHE and those without | baseline | |
Secondary | Comparison of splenic artery resistive index of cirrhotic patients with MHE compared to those without | Comparison of splenic artery resistive index measured by Doppler ultrasound of cirrhotic patients with MHE and those without | baseline | |
Secondary | Comparison of flow mediated dilation of cirrhotic patients with MHE compared to those without | Comparison of endothelial function (flow mediated dilation measured by Doppler ultrasound) of cirrhotic patients with MHE and those without | baseline | |
Secondary | Change in renal artery resistive index after treatment with rifaximin | Change in renal artery resistive index measured by Doppler ultrasound in patients with liver cirrhosis and MHE after treatment with rifaximin 1200 mg/d for 15 days | at the end of rifaximin treatment (15 days) | |
Secondary | Change in splenic artery resistive index after treatment with rifaximin | Change in splenic artery resistive index measured by Doppler ultrasound in patients with liver cirrhosis and MHE after treatment with rifaximin 1200 mg/d for 15 days | at the end of rifaximin treatment (15 days) | |
Secondary | Change in flow mediated dilation after treatment with rifaximin | Change in endothelial function (flow mediated dilation measured by Doppler ultrasound) in patients with liver cirrhosis and MHE after treatment with rifaximin 1200 mg/d for 15 days | at the end of rifaximin treatment (15 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Completed |
NCT00992290 -
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
|
Phase 1 | |
Completed |
NCT00312078 -
Effect of Yogurt on Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT04058327 -
A Study of MHE in Patients With Liver Diseases
|
||
Completed |
NCT02767622 -
Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation
|
N/A | |
Completed |
NCT03585257 -
HEAL STUDY (Hepatic Encephalopathy and Albumin Study)
|
Phase 2 | |
Recruiting |
NCT01083446 -
A Nutritional Approach to Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT02520817 -
Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study
|
N/A | |
Terminated |
NCT00811434 -
Study of Lactulose in Children With Chronic Liver Disease
|
Phase 2 | |
Completed |
NCT00375375 -
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life
|
Phase 4 | |
Completed |
NCT01069133 -
Study of Rifaximin in Minimal Hepatic Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01847651 -
Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
|
Phase 4 | |
Completed |
NCT01135628 -
Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
|
N/A | |
Completed |
NCT01223729 -
Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy
|
N/A |